Last reviewed · How we verify
CEFUROXIME SODIUM
Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent.
At a glance
| Generic name | CEFUROXIME SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1983 |
Mechanism of action
Cefuroxime works by preventing bacteria from building their cell walls, which leads to the death of the bacteria. It can still be effective even when some bacteria produce enzymes that break down similar antibiotics.
Approved indications
- Lower Respiratory Tract Infections
- Urinary Tract Infections
- Skin and Skin-Structure Infections
- Septicemia
- Meningitis
- Gonorrhea
- Bone and Joint Infections
- Preoperative Prophylaxis
Common side effects
- local reactions (thrombophlebitis)
- gastrointestinal symptoms
- diarrhea
- nausea
- rash
- pruritus
- urticaria
- positive Coombs' test
- decrease in hemoglobin and hematocrit
- transient eosinophilia
- transient neutropenia
- leukopenia
Key clinical trials
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis (NA)
- Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC) (PHASE2)
- Prevention of Surgical Site Infection in Open Paediatric Groin Surgeries Using Intravenous Prophylactic Antibiotics and Antimicrobial-coated Sutures (NA)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Compound Phellodendron Decoction May Promote Wound Healing After Anal Fistulotomy (NA)
- Effect of Topical Sinonasal Antibiotics (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CEFUROXIME SODIUM CI brief — competitive landscape report
- CEFUROXIME SODIUM updates RSS · CI watch RSS